Lantern Pharma is trading 5.53% down now at $1.02, with no clearly confirmed catalyst identified for the September 30 decline. - The September 29 close was $1.08 after volatile sessions; provided broad-market indices were modestly higher. - The company announced a registered direct offering of 3,669,725 shares or pre-funded warrants at $1.09 each, expected to raise about $4 million gross. - A concurrent private placement includes warrants for up to the same number of shares; the offering was expected to close around September 30.